← All trials
NCT01181245
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2008
- Primary completion
- May 1, 2014
- Completion date
- Jun 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- FibroGenLead sponsor
- University of PittsburghOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- Dartmouth UniversityOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- Virginia Mason Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.